首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1747036

日本血友病市场报告（按类型（血友病 A、血友病 B、血友病 C 及其他）、治疗（按需治疗、预防）、疗法（替代疗法、ITI 疗法、基因疗法）和地区）2025 年至 2033 年

Japan Hemophilia Market Report by Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), Treatment (On-Demand, Prophylaxis), Therapy (Replacement Therapy, ITI Therapy, Gene Therapy), and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 117 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024年，日本血友病市场规模达8.46亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到15.89亿美元，2025-2033年期间的复合年增长率（CAGR）为7.3%。日本强大的医疗基础设施、对早期诊断和有效管理的日益重视、不断增长的研发活动、血友病治疗的快速发展以及製药公司和科技公司之间日益增长的企业合作关係，是推动市场发展的一些关键因素。

血友病是一种罕见的遗传性疾病，其特征是血液无法正常凝结，导致长时间出血。血友病是由血液中缺乏或缺乏特定凝血蛋白（例如凝血因子 VIII 或凝血因子 IX）引起的。血友病主要分为两种：甲型血友病和B型血友病，其差异在于特定凝血因子的减少或缺失。血友病的症状多种多样，例如频繁流鼻血、易瘀青、关节疼痛、轻微损伤后严重出血。血友病的诊断可透过身体检查、病史评估、基因检测、抑制物检测以及各种实验室检查（例如凝血因子测定）进行。血友病的治疗方法多种多样，例如替代疗法、预防性治疗、基因疗法、促凝血药物、疼痛管理策略和支持性治疗。这些方法有助于预防出血发作、改善生活品质、减轻疼痛并最大限度地减少关节损伤。

日本血友病市场趋势：

日本强大的医疗基础设施使血友病患者能够更轻鬆地获得诊断和治疗，这是推动市场成长的主要因素之一。此外，由于日本医疗服务水平高，人们越来越重视早期诊断和有效管理，这对市场成长产生了积极影响。此外，在公共和私人投资的支持下，不断增长的研发活动正在推动市场成长。同时，血友病护理领域的快速发展，例如开发延长半衰期的凝血因子和探索基因治疗方案，正在为市场成长创造积极的前景。此外，日本人口预期寿命的增加需要对血友病等慢性疾病进行长期管理，这也推动了市场的成长。除此之外，政府为罕见疾病研究计画提供的各种补助和激励措施也起到了促进作用。此外，远距医疗等技术的快速发展，使得患者（尤其是居住在偏远地区的患者）能够更轻鬆地咨询专家，从而推动了市场的成长。此外，用于监测血友病相关特定变数的穿戴式健康监测技术的日益普及，也催化了市场的成长。此外，日本广泛采用国际治疗指南和方案，有助于实现护理标准化，并使治疗更具可预测性和有效性，这也促进了市场的成长。同时，政府对某些以前难以获得的治疗和药物的保险审批也给予了越来越多的支持，这也促进了市场的成长。

日本血友病市场区隔：

类型洞察：

血友病A
血友病B
血友病C
其他的

治疗见解：

一经请求
预防

治疗见解：

替代疗法
ITI 治疗
基因治疗

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

日本血友病市场目前表现如何？未来几年将如何表现？
COVID-19 对日本血友病市场有何影响？
日本血友病市场如何按类型划分？
日本血友病市场依治疗类型划分是怎样的？
日本血友病市场依治疗方法的划分是怎样的？
日本血友病市场的价值链分为哪些阶段？
日本血友病的关键驱动因素和挑战是什么？
日本血友病市场的结构是怎么样的？主要参与者是谁？
日本血友病市场的竞争程度如何？

本报告回答的关键问题：

日本血友病市场目前表现如何？未来几年将如何表现？
COVID-19 对日本血友病市场有何影响？
日本血友病市场如何按类型划分？
日本血友病市场依治疗类型划分是怎样的？
日本血友病市场依治疗方法的划分是怎样的？
日本血友病市场的价值链分为哪些阶段？
日本血友病的关键驱动因素和挑战是什么？
日本血友病市场的结构是怎么样的？主要参与者是谁？
日本血友病市场的竞争程度如何？

The Japan hemophilia market size reached USD 846.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,589.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033. The robust healthcare infrastructure in Japan, increasing focus on early diagnosis and effective management, rising research and development (R&D) activities, rapid advancements in hemophilia care, and the growing corporate partnerships between pharmaceutical companies and tech firms represent some of the key factors driving the market.

Hemophilia refers to a rare genetic disorder characterized by the inability of the blood to clot properly, leading to prolonged bleeding. It is caused by the deficiency or absence of specific clotting proteins, such as Factor VIII or Factor IX, in the blood. It primarily occurs in two forms, such as Hemophilia A and Hemophilia B, distinguished by the specific clotting factor that is either reduced or missing. Hemophilia exhibits various symptoms such as frequent nosebleeds, easy bruising, joint pain, and severe bleeding from minor injuries. It is diagnosed through physical examination, medical history evaluation, genetic testing, inhibitor testing, and various laboratory tests, such as clotting factor assays. Hemophilia is treated using multiple methods, such as replacement therapy, prophylactic treatment, gene therapy, clot-promoting medications, pain management strategies, and supportive care. They aid in preventing bleeding episodes, improving quality of life, reducing pain, and minimizing joint damage.

Japan Hemophilia Market Trends:

The robust healthcare infrastructure in Japan, facilitating easier access to diagnostics and treatment for hemophilia patients, is one of the major factors contributing to the market growth. Moreover, the increasing focus on early diagnosis and effective management of the condition due to the high standard of healthcare services in the country is positively impacting the market growth. Additionally, the rising research and development (R&D) activities, backed by public and private investments, are providing a thrust to the market growth. In line with this, rapid advancements in hemophilia care, such as the development of extended half-life clotting factors and exploration of gene therapy options, are creating a positive outlook for the market growth. Furthermore, the increasing life expectancy of the population in Japan, requiring the need for long-term management of chronic conditions like hemophilia, is providing a thrust to the market growth. In addition to this, the implementation of various government grants and incentives for research projects focused on rare diseases is acting as a growth-inducing factor. Along with this, rapid advancements such as telemedicine, which make it easier for patients to consult with specialists, especially for those living in remote areas, are boosting the market growth. Besides this, the increasing prevalence of wearable technologies for health monitoring that are customized to monitor specific variables related to hemophilia is catalyzing the market growth. Apart from this, the widespread adoption of international treatment guidelines and protocols in Japan that help standardize care and make treatment more predictable and effective is bolstering the market growth. In line with this, the growing government aid in insurance approvals for certain kinds of treatments and medications that were earlier difficult to access is fostering the market growth.

Japan Hemophilia Market Segmentation:

Type Insights:

Hemophilia A
Hemophilia B
Hemophilia C
Others

Treatment Insights:

On-Demand
Prophylaxis

Therapy Insights:

Replacement Therapy
ITI Therapy
Gene Therapy

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan hemophilia market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan hemophilia market?
What is the breakup of the Japan hemophilia market on the basis of type?
What is the breakup of the Japan hemophilia market on the basis of treatment?
What is the breakup of the Japan hemophilia market on the basis of therapy?
What are the various stages in the value chain of the Japan hemophilia market?
What are the key driving factors and challenges in the Japan hemophilia?
What is the structure of the Japan hemophilia market and who are the key players?
What is the degree of competition in the Japan hemophilia market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Hemophilia Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Hemophilia Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Hemophilia Market - Breakup by Type

6.1 Hemophilia A
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Hemophilia B
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Hemophilia C
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Others
- 6.4.1 Historical and Current Market Trends (2019-2024)
- 6.4.2 Market Forecast (2025-2033)

7 Japan Hemophilia Market - Breakup by Treatment

7.1 On-Demand
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Prophylaxis
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)

8 Japan Hemophilia Market - Breakup by Therapy

8.1 Replacement Therapy
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 ITI Therapy
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Gene Therapy
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)

9 Japan Hemophilia Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Service Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Service Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Service Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Service Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Service Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Hemophilia Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis